The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

Paolo A. Ascierto, Paolo Bruzzi, Alexander Eggermont, Omid Hamid, Hussein A. Tawbi, Alexander Van Akkooi, Alessandro Testori, Corrado Caracò, Igor Puzanov, Francesco Perrone

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

1 Citaat (Scopus)


The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

Originele taal-2Engels
TijdschriftJournal of Translational Medicine
Nummer van het tijdschrift1
StatusGepubliceerd - 10 mei 2019
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018'. Samen vormen ze een unieke vingerafdruk.

Citeer dit